Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog® Consistently Across Study Populations: A Pooled Analysis of Pharmacokinetic and Glucodynamic Data
Tóm tắt
Ultra rapid lispro (URLi) is a novel insulin lispro formulation developed to more closely match physiological insulin secretion and improve postprandial glucose control. This pooled analysis compared the pharmacokinetics and glucodynamics between URLi and Humalog® in healthy subjects and patients with type 1 or type 2 diabetes mellitus. The analysis included four randomized, double-blind, crossover, single-dose studies (healthy subjects [n = 74], patients with type 1 diabetes [n = 78], and type 2 diabetes [n = 38]) evaluating subcutaneous doses of 7, 15, or 30 U of URLi and Humalog during an 8- to 10-h euglycemic clamp procedure. The pooled analysis showed an ~ 5-min faster onset of appearance, an ~8-fold greater exposure in the first 15 min, a 43% reduction in exposure beyond 3 h, and a 68-min shorter exposure duration with URLi vs Humalog across all study populations and dose range. Compared with Humalog, URLi had a 10-min faster onset of action, a 3-fold greater insulin action in the first 30 min, a 35% reduction in insulin action beyond 4 h, and a 44-min shorter duration of action across all populations and dose range. Overall exposure and insulin action were similar between URLi and Humalog for each dose level and study population. Across the studied populations and dose range, URLi consistently demonstrated a faster absorption, reduced late exposure, and overall shorter exposure duration compared with Humalog. Similarly, URLi demonstrated earlier insulin action while reducing late insulin action and shorter insulin action compared with Humalog across the study populations and dose range. NCT02942654 (registered: 21 October, 2016), NCT03286751 (registered: 15 September, 2017), NCT03166124 (registered: 23 May, 2017), and NCT03305822 (registered: 5 October, 2017).
Tài liệu tham khảo
Ceriello A. Glucose variability and diabetic complications: is it time to treat? Diabetes Care. 2020;43(6):1169–71.
Hirsch IB. Glycemic variability and diabetes complications: does it matter? Of course it does! Diabetes Care. 2015;38(8):1610–4.
Umpierrez GE, Kovatchev PB. Glycemic variability: how to measure and its clinical implication for type 2 diabetes. Am J Med Sci. 2018;356(6):518–27.
American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes: 2020. Diabetes Care. 2020;43(Suppl 1):S14-31.
Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Diabetes Control and Complications Trial Research Group, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.
International Diabetes Federation Guideline Development Group. Guideline for management of postmeal glucose in diabetes. Diabetes Res Clin Pract. 2014;103(2):256–68.
Madsbad S. Impact of postprandial glucose control on diabetes-related complications: how is the evidence evolving? J Diabetes Complications. 2016;30(2):374–85.
American Diabetes Association. Pharmacologic approaches to glycemic treatment. Standards of medical care in diabetes: 2020. Diabetes Care. 2020;43(Suppl 1):S98–110.
Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–701.
Guerci B, Sauvanet JP. Subcutaneous insulin: pharmacokinetic variability and glycemic variability. Diabetes Metab. 2005;31(4 Pt 2):4s7-24.
Grunberger G. Insulin analogs: are they worth it? Yes! Diabetes Care. 2014;37(6):1767–70.
Heinemann L, Heise T, Wahl LC, Trautmann ME, Ampudia J, Starke AA, et al. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med. 1996;13(7):625–9.
Heinemann L, Muchmore DB. Ultrafast-acting insulins: state of the art. J Diabetes Sci Technol. 2012;6(4):728–42.
Kalra S, Gupta Y. Ultra-fast acting insulin analogues. Recent Pat Endocr Metab Immune Drug Discov. 2014;8(2):117–23.
Eli Lilly and Company. Humalog (insulin lispro injection): highlights of prescribing information. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020563s172,205747s008lbl.pdf. Accessed 24 Oct 2019.
Pratt E, Leohr J, Heilmann C, Johnson J, Landschulz W. Treprostinil causes local vasodilation, is well tolerated, and results in faster absorption of insulin lispro (abstract 975-P). Diabetes. 2017;66(Suppl 1):A253.
Michael M, Zhang C, Siesky A, Cox A, Sperry A, Hansen R, et al. Exploration of the mechanism of accelerated absorption for a novel insulin lispro formulation. Diabetes. 2017;66(Suppl 1):A250.
Heise T, Linnebjerg H, Coutant D, LaBell E, Zijlstra E, Kapitza C, et al. Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: a phase 1 randomized, crossover study. Diabetes Obes Metab. 2020;22(10):1789–98.
Klaff L, Cao D, Dellva MA, Tobian J, Miura J, Dahl D, et al. Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: results from the 26-week PRONTO-T1D study. Diabetes Obes Metab. 2020;22(10):1799–807.
Blevins T, Zhang Q, Frias JP, Jinnouchi H, Chang AM. Randomized double-blind clinical trial comparing ultra rapid lispro with lispro in a basal-bolus regimen in patients with type 2 diabetes: PRONTO-T2D. Diabetes Care. 2020;43(12):2991–8.
Leohr J, Dellva MA, LaBell ES, Coutant DE, Klein O, Plum-Moerschel L, et al. Pharmacokinetic and glucodynamic responses of ultra rapid lispro (URLi) vs Humalog (Lispro) across a clinically relevant range of subcutaneous doses in healthy subjects. Clin Ther. 2020;42(9):1762-77.e4. https://doi.org/10.1016/j.clinthera.2020.07.005.
Linnebjerg H, Zhang Q, LaBell E, Dellva MA, Coutant DE, Hövelmann U, et al. Pharmacokinetics and glucodynamics of ultra rapid Lispro (URLi) versus Humalog® (Lispro) in younger adults and elderly patients with type 1 diabetes mellitus: a randomised controlled trial. Clin Pharmacokinet. 2020;59(12):1589–99. https://doi.org/10.1007/s40262-020-00903-0.
Leohr J, Dellva MA, Coutant DE, LaBell E, Heise T, Andersen G, et al. Pharmacokinetics and glucodynamics of ultra rapid lispro (URLi) versus Humalog® (Lispro) in patients with type 2 diabetes mellitus: a phase I randomised, crossover study. Clin Pharmacokinet. 2020;59(12):1601–10. https://doi.org/10.1007/s40262-020-00901-2.
Haidar A, Duval C, Legault L, Rabasa-Lhoret R. Pharmacokinetics of insulin aspart and glucagon in type 1 diabetes during closed-loop operation. J Diabetes Sci Technol. 2013;7(6):1507–12.
Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881–5.
Krzymien J, Ladyzynski P. Insulin in type 1 and type 2 diabetes: should the dose of insulin before a meal be based on glycemia or meal content? Nutrients. 2019;11(3):607.